{"id":687878,"date":"2022-09-22T06:33:08","date_gmt":"2022-09-22T10:33:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/"},"modified":"2022-09-22T06:33:08","modified_gmt":"2022-09-22T10:33:08","slug":"design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/","title":{"rendered":"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CARLSBAD, Calif., Sept.  22, 2022  (GLOBE NEWSWIRE) &#8212; Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that Jo\u00e3o Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC.<\/p>\n<p>A live webcast will be available in the investor section of the company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nls5VyMTZXodvTH42E7ldG4m0tAchvNda5hbQnuId-OJ__VEDvehMRH0xZRHWD4dowJuKCVT3hIt4wLpA-bWRA==\" rel=\"nofollow noopener\" target=\"_blank\">www.designtx.com<\/a> and will be archived for 30 days following the presentation.<\/p>\n<p>\n        <strong>About Design Therapeutics<\/strong><br \/>\n        <br \/>Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC\u2122 gene targeted chimera small molecules. The company\u2019s GeneTAC\u2122 molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design\u2019s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Investors:<br \/>Chelcie Lister<br \/>THRUST Strategic Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ikJC9NhrSqA17cI42c-EdmrYYOrBAHEVUXE_XLOP0brDfEEO684um4VCtrtoAbvyyUv89al5S-2C-e2rtRwoabsIFjPw2JIDzSNwXsVQBUE=\" rel=\"nofollow noopener\" target=\"_blank\">chelcie@thrustsc.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTJlZmM3MGEtNmY2Yi00MjVmLWJhOTItNDk2NDNmMmI4YzhlLTEyMTgzOTI=\/tiny\/Design-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that Jo\u00e3o Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC. A live webcast will be available in the investor section of the company&#8217;s website at www.designtx.com and will be archived for 30 days following the presentation. About Design Therapeutics Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC\u2122 gene targeted chimera small &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-687878","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that Jo\u00e3o Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC. A live webcast will be available in the investor section of the company&#8217;s website at www.designtx.com and will be archived for 30 days following the presentation. About Design Therapeutics Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC\u2122 gene targeted chimera small &hellip; Continue reading &quot;Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T10:33:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit\",\"datePublished\":\"2022-09-22T10:33:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/\"},\"wordCount\":210,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/\",\"name\":\"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk=\",\"datePublished\":\"2022-09-22T10:33:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/","og_locale":"en_US","og_type":"article","og_title":"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit - Market Newsdesk","og_description":"CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that Jo\u00e3o Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC. A live webcast will be available in the investor section of the company&#8217;s website at www.designtx.com and will be archived for 30 days following the presentation. About Design Therapeutics Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC\u2122 gene targeted chimera small &hellip; Continue reading \"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-22T10:33:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit","datePublished":"2022-09-22T10:33:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/"},"wordCount":210,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/","name":"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk=","datePublished":"2022-09-22T10:33:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MDg3MSM1MTY0ODc1IzIyMDY4Mzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/design-therapeutics-to-present-at-the-2022-jefferies-cell-and-genetic-medicine-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=687878"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687878\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=687878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=687878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=687878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}